Newsroom
News and press releases
Product launches, scientific publications, events, partnerships and financial announcements.
2026
- Company newsBusiness Wire ↗ABL Diagnostics Becomes ABL Texcell Diagnostics
- Company newsEIN Presswire ↗ABL Diagnostics Announces UltraGene Respiratory Pathogens 21 After CE-IVD Registration by ABL SA Luxembourg
- Company newsEIN Presswire ↗ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations
- Company newsNewsletter ↗DeepChek® & HybridChek TB Assays & SoftwareComplete Coverage for Tuberculosis Drug Resistance Testing by Amplicon & Hybrid Capture NGS Sequencing.
- Company newsEIN Presswire ↗ABL Diagnostics Confirms BSI Partnership for IVDR Transition and Long-Term Availability of its CE-IVD Medical Devices
- Company newsEIN Presswire ↗ABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral Resistance
- Company newsBusiness Wire ↗ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031
- Company newsEIN Presswire ↗ABL Diagnostics Showcases Scientific Progress at EMHH 2026, Supporting Strategic Positioning in Molecular Technologies
- Company newsEIN Presswire ↗ABL Diagnostics Advances Platform-Agnostic NGS Strategy Through DeepChek® Verification on Element Biosciences’ AVITI™
- Company newsEIN Presswire ↗ABL Diagnostics Deepens Laboratory Footprint with Launch of HybridChek for HIV and Tuberculosis Whole Genome Sequencing
- Company newsEIN Presswire ↗ABL Diagnostics Broadens UltraGene Syndromic qPCR Portfolio
- Company newsBusiness Wire ↗ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026 (EN)
- Company newsEIN Presswire ↗ABL Diagnostics Advances NGS for CMV Resistance Monitoring at SEIMC 2026
- Company newsEIN Presswire ↗UltraGene Ebola: Multiplex qPCR for Outbreak Preparedness
- Company newsEIN Presswire ↗In FrenchABL Diagnostics et le CHRU Nancy : premier bilan positif pour le projet PREDAVIR après 6 mois
- Company newsEIN Presswire ↗ABL Diagnostics Drives EMEA Expansion with VELA Diagnostics Partnership
- Company newsEIN Presswire ↗ABL Diagnostics Unveils Next-Generation HIV Genotyping Innovation with the Industry’s Broadest Portfolio
- Company newsICAR 2026 - Persistent APOBEC activity in children with longstanding HIV infection: characterization and correlation with clinical outcome
- Company newsEIN Presswire ↗ABL Diagnostics Announces Strategic AI Roadmap to Advance Molecular Research and Global Data Security
2025
- Company newsABL Diagnostics Webinar SeriesOfficial Presentation of the DeepChek® HPV Messenger RNA Genotyping Assay Webinar from June 26, 11h00 CET / Paris time
- Company newsMolecular detection of hrHPV-induced high-grade squamous intraepithelial lesions of the cervix through a targeted RNA next generation sequencing assayJulia Faillace Thiesen , Elise Jacquemet , Pascal Campagne, Denis Chatelain, Etienne Brochot, Yves‑Edouard Herpe , Nolwenn M. Dheilly , Fabrice Bouilloux, Bénédicte Rognon, Alexandre Douablin, Guillaume Leboucher ,…
- Company newsABL Diagnostics Signs Exclusive Distribution Agreement with Riken Genesis to Expand Microbiology Genotyping in JapanABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd. ( ). Under this…
2024
- Company newsABL Diagnostics Webinar SeriesREAL LIFE EXPERIENCE: The relevance of ultradeep sequencing for low HIV‐1 viral loads and proviruses in the clinical setting Webinar from Tuesday November 19, 2024 – 4pm CEST
- Company newsAdvancedDx Biological Laboratories USA Inc. and Complete Genomics LLC to co-market NGS microbiology solution in the U.S.NEWBURYPORT, MA, UNITED STATES, September 23, 2024 / EINPresswire.com / -- AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company…
- Company newshttps://pubmed.ncbi.nlm.nih.gov/39185639/The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting Alizée Foury 1 2 , Aline Saunier 2 , Audrey Taverniers 2 , Nathalie Pinet 2 , Thomas Josse 2 , Eliette Jeanmaire 3 ,…
- Company newsABL Diagnostics continues its surveillance of SARS-CoV-2 variants and prepares for any resurgence of COVID-19 outbreaksWOIPPY, FRANCE, August 21, 2024 / EINPresswire.com / -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories…
- Company newsABL Diagnostics expands its network of exclusive distributors and appoints INTERLUX OÜ in EstoniaWOIPPY, FRANCE, July 16, 2024 / EINPresswire.com / -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is…
- Company newsABL Diagnostics Webinar SeriesManagement of the APOBEC Mutations through the DeepChek-HIV Proviral DNA Genotyping Assays & Software OVERVIEW & USERS EXPERIENCE Webinar from Thursday June 13, 2024 – 4pm CEST
- Company newsABL Diagnostics Deeply Involved to Support Fight Against RSV InfectionWoippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the involvement…
- Company newsABL Diagnostics Showcases Disruptive Clinical Genotyping Scientific Communications at the European Meeting on HIV and Hepatitis (EMH) 2024Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is participating to the European…
- Company newsABL Diagnostics and Laborama officially appointed to offer NGS genotyping solutions to the National Laboratory for Public Health (NLPH) in Lithuania.Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the…
- Company newsMGI Showcases Life Science Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL DiagnosticsBarcelona, Spain, 29 April 2024 – MGI Tech (MGI), a company committed to building core tools and technology to lead life science, today introduced the latest addition to its range of sequencers, the portable and…
- Company newsABL DIAGNOSTICS: LIQUIDITY CONTRACT WITH ALLINVEST SECURITIESABL DIAGNOSTICS (ABLD) has announced the signing of a liquidity contract with ALLInvest Securities, effective from the morning of 24.04.2024. ABL Diagnostics SA (EPA:ABLD)WOIPPY, FRANCE, April 24, 2024 /…
- Company newsAdvancedDx Biological Laboratories USA Inc. and Medline Industries, LP to distribute Next Generation Sequencing (NGS) Prep Kits in the U.S.Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software…
- Company newsAdvancedDx Biological Laboratories USA Inc. expands its logistics and storage capacity for supporting and managing third-parties’ clinical trials in the USANewburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics S.A. (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and…
- Company newsABL Diagnostics appoints PALEX to offer NGS genotyping applications & Sanger to microbiology laboratories in Spain.Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is announcing today the execution of a…
- Company newsBlock trading of ABL Diagnostics ordinary shares (ABLD, Euronext, compartment B)Woippy, le 4 mars 2024 à 8h ABL Diagnostics (FR001400AHX6) ("ABLD" or the "Company") announced today that a total of three block transactions since August 2023 for a total of 59,651 shares of its common stock have been…
- Company newsABL Diagnostics and AB ANALITICA join forces to offer microbiology genotyping solutions in Italy.Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”) , a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the…
- Company newsCarrying Out Research About HIV Whole Genome using a Kit Now Available in the USAAccess to a comprehensive Next Generation Sequencing (NGS) kit for HIV Whole Genome genotyping. Ability to screen genomic variations in all HIV-1 genome genes targeted by current and under development HIV-1 inhibitors.…
- Company newsAdvancedDx Biological Laboratories USA Inc. announces its new temperature-controlled warehouse in the USANewburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software…
- Company newsABL Diagnostics Webinar Series - Session IIINTRODUCING THE DEEPCHEK GENOTYPING TECHNOLOGY OVERVIEW & USERS EXPERIENCE Webinar from Tuesday January 30, 2024 – 4pm CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par notre équipe et par…
- Company newsIn FrenchABL Diagnostics Webinar SeriesREVUE DE LA TECHNOLOGIE DE GENOTYPAGE DEEPCHEK PRESENTATION & EXPERIENCES UTILISATEUR Webinaire réalisé le mardi 23 janvier 2024 – 10h00 CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par…
- Company newsABL Diagnostics announces the release of its DeepChek®-HPV Assay, to be used for Human Papillomavirus screening, genotyping, and discrimination through sequencing.Next Generation Sequencing (NGS) assay and software to screen, to genotype and to discriminate the Human Papillomavirus. ABL Diagnostics strives to offer innovative solutions providing to healthcare personnel relevant…
- Company newsABL Diagnostics announces new releases of its DeepChek®, ViroScore® and MicrobioChek® software platforms for microbiology clinical genotypingABL Diagnostics uses its application-specific expertise to provide Information System (IT) services & software applications to all microbiology laboratories. From Capillary Electrophoresis (SANGER) to Next Generation…
2023
- Company newsABL DIAGNOSTICS INTRODUCING CRISPRCHEK - A NEW LINE OF ASSAYS USING THE CRISPR TECHNOLOGYABL Diagnostics keeps innovating and developing its Research & Development activities through a new line of PCR detection assays, called CRISPRChek, using the disruptive CRISPR technology. First CRISPRChek prototypes to…
- Company newsDeepChek® Assay Whole Genome HDV Genotyping successfully passed 2023 QCMD quality control program and obtained a "highly satisfactory" score for the detection of Hepatitis Delta.
- Company newsABL DIAGNOSTICS EXPANDS ITS HIV GENOTYPING ASSAYS OFFERINGABL Diagnostics keeps investing to strengthen its expertise and leadership in HIV drug resistance testing by genotyping through the release of a new revolutionary kit, DeepChek® Assay HIV-1 Full PR/RT/INT Drug…
- Company newsABL Diagnostics expands its commercial network and collaborations to offer unique Sanger & NGS based microbiology genotyping assays and software worldwide.ABL Diagnostics spreading the DeepChek® technology (suite of Sanger & NGS assays and software systems) to laboratories performing infectious diseases genotyping. The company continues to expand its network of…
- Company newsDeepChek ® HCV / HBV / HDV Assays & SoftwareDeepChek ® HCV / HBV / HDV Assays & Software Send Me More information
- Company newsNew kit Available !! Genotyping of the Full HIV-1 pol Gene with PR+RT+INT Regions in One Single PCR ReactionNew kit Available !! Genotyping of the Full HIV-1 pol Gene with PR+RT+INT Regions in One Single PCR Reaction Send Me More information
- Company newsABL Diagnostics: A partner of choice for your scientific projectsABL Diagnostics: A partner of choice for your scientific projects APHP (Assistance Publique Hôpitaux de Paris) // France Epidemiological and Molecular evolution of the HIV-1 CRF94: Birth of CRF 132 ♦♦♦ CHU…
- Company newsHigh-Resolution Bacterial identification through Whole 16s RNA Next Generation SequencingHigh-Resolution Bacterial identification through Whole 16s RNA Next Generation Sequencing
- Company newsNew Distribution Partnership with Biosistemi Grupa D.D.O. for 5 territories in the BalkansNew Distribution Partnership with Biosistemi Grupa D.D.O. for 5 territories in the Balkans We are pleased to announce that we entered into a distribution agreement of ABL’s Diagnostics line of products, including the…
- Company newsMeet us at the 11th German-Austrian AIDS Congress (DÖAK 2023)Meet us at the 11th German-Austrian AIDS Congress (DÖAK 2023) Sehen wir uns beim #DÖAK ? Vom 23. bis 25. März 2023 sind wir beim 11. Deutsch-Österreichischen AIDS-Kongress in Bonn! Besuchen Sie uns am Stand und freuen…
- Company newsNew Scientific Publication: From Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using in Vitro Diagnostic (IVD Assays and SoftwareNew Scientific Publication: From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software We are pleased to share the…
2022
- Company newsStrengthening the historic partnership with Roche diagnostics Spain to extend the offer to the Spanish marketStrengthening the historic partnership with Roche diagnostics Spain to extend the offer to the Spanish market ABL Diagnostics, the leading provider of genotyping diagnostic tests for infectious diseases, herewith…
- Company newsWEB TV INterview: ABL Diagnostics fait le point sur son activitéWeb TV Interview: ABL Diagnostics fait le point sur son activité We are happy to share our first webTV interview during which we have explained ABL Diagnostics activity and the development of our market. Co-founders of…
- Company news<strong>Interest of HIV-1 Next-Generation Sequencing in a diagnosis laboratory in France</strong>Interest of HIV-1 Next-Generation Sequencing in a diagnosis laboratory in France The objective of this study consists in the analyse the interest of HIV NGS sequencing, targeted , protease (PR), reverse transcriptase…
- Company newsABL Diagnostics increases its production capacities and its resilience thanks to the "France Relance" programABL Diagnostics increases its production capacities and its resilience thanks to the "France Relance" program ABL Diagnostics is pleased to announce that a substantial increase of its molecular assays production…
- Company newsABL Diagnostics signed a Channel Partners Agreement with IlluminaABL Diagnostics signed a Channel Partner Agreement with Illumina to offer, combined with ABL Diagnostics’ DeepChek™ products, on the iSeq™ 100 and MiSeq™ next-generation sequencing platforms to microbiology laboratories…
- Company newsMeet us at MEDICA 2022Meet us at MEDICA 2022 Meet us at MEDICA 2022 and Discover our Microbiology Genotyping Solutions ABL will be attending the next MEDICA forum in Düsseldorf from 14 - 17 November 2022 (Luxembourg Ministry of Economy -…
- Company newsABL Diagnostics sponsored the NTDD Symposium in UtrechtABL Diagnostics sponsored the NTDD Symposium in Utrecht (NL) ABL Diagnostics sponsored the NTDD Symposium in Utrecht and presented the DeepChek® kit for Tuberculosis Genotyping & Drug Resistance through NGS sequencing…
- Company newsSet up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas.Set up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas. We would like to thank our local representative in Uruguay Biko…
- Company newsABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial communityABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial community ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX…
- Company newsIn FrenchAtout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l'activité diagnostic médical d'ABL France à hauteur de 28 m€Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l'activité diagnostic médical d'ABL France à hauteur de 28 m€ ABL DIAGNOSTICS développe, fabrique et commercialise des kits de tests de diagnostic…
- Company newsABL Diagnostics at the Federation of Infection Societies congressABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including: Publication #1 (Poster…
- Company newsAdvanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SAAdvanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL…
- Company newsWHO algorithm v2021-06 for Tuberculosis resistance now available!WHO algorithm v2021-06 for Tuberculosis resistance now available! We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for…
- Company newsABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™”
- Company newsDeepChek-HIV Whole genome Sequencing assay now CE IVD marked !DeepChek-HIV Whole genome Sequencing assay now CE IVD marked !
- Company newsNew Distribution Partners in Georgia & Paraguay !This week we are proud to have two new Distribution Partners on our side : - ELTA 90 Medical Genetics in Georgia - Infotec in Paraguay Both agreements will cover all ABL’s Diagnostics line of products, including the…
- Financial & regulatedIn FrenchSignature d'un traité de fusionSignature d’un traité de fusion Le Conseil d’administration de la société ABL Diagnostics (la « Société »), réuni le 13 juin 2022, a approuvé le projet de fusion-absorption aux termes duquel il est prévu que la Société…
- Financial & regulatedIn FrenchABL Dx – Projet de traité de fusion entre ABL Diagnostics et Advanced Biological Laboratories FedialisAux termes d’un acte sous seing privé du 14 juin 2022, les sociétés ABL Diagnostics et Advanced Biological Laboratories Fedialis (« ABL France »), ont établi un projet de fusion par voie d’absorption d’ABL France par…
- Financial & regulatedABL Dx – Projet de traité de fusion entre ABL Diagnostics et Advanced Biological Laboratories FedialisDownload Document Download the document (PDF)
- Company newsNew distribution partnership in Ethiopia & BoliviaWe are pleased to announce that we entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software: – With Retina Pharmaceuticals in Ethiopia; – With…
- Company newsDEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKEDWe are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked !
- Financial & regulatedIn FrenchDIVISION PAR 8 DE LA VALEUR NOMINALE DES ACTIONS ABL DX LE 18 MAI 2022L’Assemblée Générale Mixte des actionnaires de la société ABL Diagnostics (ABL Dx) (anciennement Etablissements Fauvet Girel), tenue le 23 mars 2022, a décidé de diviser par 8 la valeur nominale des actions ABL Dx et…
- Financial & regulatedIn FrenchInformations sur la composition du Conseil d'administrationDownload the document (PDF)
- Company newsPresentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to…
- Financial & regulatedIn FrenchABL Diagnostics - Changement de dénomination socialeL’Assemblée Générale Mixte des actionnaires de la société Etablissements Fauvet Girel tenue le 23 mars 2022 a décidé de modifier la dénomination sociale de la société qui est désormais dénommée ABL Diagnostics, comme…
- Financial & regulatedIn FrenchÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont…
- Company newsABL announce a new Distribution Agreement with Geneplus Co Ltd in ThailandAdvanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays…
- Financial & regulatedIn FrenchRÉSULTAT DE L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIREL, INITIÉE PAR ADVANCED BIOLOGICAL LABORATORIES S.AL’offre publique d’achat simplifiée visant les actions ETABLISSEMENTS FAUVET-GIREL, initiée le 23 décembre 2021 par ADVANCED BIOLOGICAL LABORATORIES SA (« ABL SA »), s’est clôturée le 7 janvier 2022. A l’occasion de…
- Company newsABL Announces Distribution Agreement with Hayleys Lifesciences in Sri LankaAdvanced Biological Laboratories (ABL) S.A. and Hayleys Lifesciences are pleased to announce that they entered into an exclusive distribution agreement of ABL's Diagnostics line of products, including the DeepChek®…
2021
- Financial & regulatedIn FrenchINFORMATIONS RELATIVES AUX CARACTÉRISTIQUES NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LA SOCIÉTÉ ADVANCED BIOLOGICAL LABORATORIES S.ALe présent document complète la note d’information (la « Note d’Information ») relative à l’offre publique d’achat simplifiée initiée par ADVANCED BIOLOGICAL LABORATORIES SA visant les actions de la société…
- Financial & regulatedIn FrenchINFORMATIONS RELATIVES AUX CARACTÉRISTIQUES NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIRELLe présent document incorpore par référence le rapport financier annuel relatif à l’exercice clos le 31 décembre 2020 (le « Rapport Financier Annuel ») et le rapport financier semestriel relatif à l’exercice clos le 31…
- Financial & regulatedIn FrenchNOTE EN RÉPONSE ÉTABLI PAR LA SOCIÉTÉ ADVANCED BIOLOGICAL LABORATORIESLa présente note d’information est disponible sur les sites Internet de l’AMF ( www.amf-france.org ) et de la société ADVANCED BIOLOGICAL LABORATORIES SA ( www.ablsa.com ) et peut être obtenue sans frais auprès…
- Company newsIn FrenchNOTE EN RÉPONSE ÉTABLI PAR LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIRELLa présente note en réponse est disponible sur les sites Internet de l’AMF ( www.amf-france.org ), de la société ETABLISSEMENTS FAUVET-GIREL ( www.fauvet-girel.fr ) et de la société ADVANCED BIOLOGICAL LABORATORIES SA (…
- Financial & regulatedIn FrenchPROJET DE NOTE EN RÉPONSE ÉTABLI PAR LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIRELLe présent projet de note en réponse a été établi et déposé auprès de l’Autorité des marchés financiers (l’« AMF ») le 8 décembre 2021 conformément aux dispositions des articles 231-19 et 231-26 de son règlement…
- Financial & regulatedIn FrenchPROJET D’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉ VISANT LES ACTIONS DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIRELLe présent projet de note d’information a été établi et déposé auprès de l’Autorité des marchés financiers (l’« AMF ») le 10 novembre 2021 conformément aux dispositions des articles 231-13, 231-16 et 231-18 de son…
- Company newsABL ANNOUNCES DISTRIBUTION AGREEMENT WITH MEDSOL IN SAUDI ARABIAABL announces Distribution Agreement with Medsol in Saudi Arabia Advanced Biological Laboratories (ABL) S.A. and Medsol Corporation are pleased to announce that they entered into an exclusive distribution agreement of…
- Financial & regulatedACQUISITION OF A CONTROLLING STAKE IN ETABLISSEMENTS FAUVET GIREL BY ADVANCED BIOLOGICAL LABORATORIESETABLISSEMENTS FAUVET GIREL (the ” Company “) hereby informs its shareholders that STE PARISIENNE DE CONSTRUCTION ET DE LOCATION (SPACLO), holding 91.47% of the Company’s capital, and seven individuals, jointly holding…
- Financial & regulatedIn FrenchACQUISITION DU BLOC DE CONTRÔLE DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET GIREL PAR LA SOCIÉTÉ ADVANCED BIOLOGICAL LABORATORIES S.ALa Société ETABLISSEMENTS FAUVET GIREL (la « Société ») informe ses actionnaires que la société STE PARISIENNE DE CONSTRUCTION ET DE LOCATION (SPACLO), détenant 91,47% du capital de la Société, ainsi que sept personnes…
